HIV lipodystrophy and its metabolic consequences: implications for clinical practice

References

• Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702–10
   PubMed Web of Science ®Google Scholar
• Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005;21:1717–25
   PubMed Web of Science ®Google Scholar
• World Health Organisation and Joint United Nations Programme on HIV/AIDS. Treating 3 million by 2005: making it happen, the WHO strategy, 2003. Geneva: World Health Organisation
   Google Scholar
• Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725–30
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22–9
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60
   PubMed Web of Science ®Google Scholar
• Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007;146:87–95
   PubMed Web of Science ®Google Scholar
• Vella S, Palmisano L. HIV eradication revisited. Expert Opin Investig Drugs 2000;9:193–7
   PubMed Web of Science ®Google Scholar
• Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962–9
   Google Scholar
• Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV- 1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881–3
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093–9
   PubMed Web of Science ®Google Scholar
• Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001;2:166–73
   PubMedGoogle Scholar
• Milinkovic A, Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother 2005;56:6–9
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 2003;37(Suppl 2):S43–6
   PubMedGoogle Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51–8
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659–67
   Google Scholar
• Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000;23:57–76
   Google Scholar
• Wanke CA, Falutz JM, Shevitz A, et al. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002;34:248–59
   PubMed Web of Science ®Google Scholar
• Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003;32:298–302
   PubMed Web of Science ®Google Scholar
• Paparizos VA, Kyriakis KP, Botsis C, et al. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000;14:903–5
   PubMed Web of Science ®Google Scholar
• Sharp M. Metabolic complications associated with HIV disease. Posit Aware 2003;14:32–6
   PubMedGoogle Scholar
• Executive Summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726–34
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Schumacher A, Sandvik L, et al. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 2006;38:682–9
   PubMed Web of Science ®Google Scholar
• Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005;118\(Suppl 2):3S–8
   Google Scholar
• Brown TT, Cofrancesco J. Metabolic abnormalities in HIV-infected patients: an update. Curr Infect Dis Rep 2006;8:497–504
   PubMedGoogle Scholar
• Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 2003;10:121–8
   PubMedGoogle Scholar
• Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811–22
   PubMed Web of Science ®Google Scholar
• Currier J, Carpenter C, Daar E, et al. Identifying and managing morphologic complications of HIV and HAART. AIDS Read 2002;12:114–5
   PubMedGoogle Scholar
• Lemieux S, Despres JP. Metabolic complications of visceral obesity: contribution to the aetiology of type 2 diabetes and implications for prevention and treatment. Diabete Metab 1994;20:375–93
   PubMed Web of Science ®Google Scholar
• Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871–5
   PubMed Web of Science ®Google Scholar
• Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974;32:77–97
   PubMed Web of Science ®Google Scholar
• Andrade S, Lan SJ, Engelson ES, et al. Use of a Durnin-Womersley formula to estimate change in subcutaneous fat content in HIV-infected subjects. Am J Clin Nutr 2002;75:587–92
   PubMed Web of Science ®Google Scholar
• Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:228–37
   PubMedGoogle Scholar
• Gravante G, Lo GS. Bichat’s fat-pad: correlations with some anthropometric parameters. Ann Hum Biol 1997;24:181–5
   PubMed Web of Science ®Google Scholar
• Padilla S, Gallego JA, Masia M, Gutierrez F. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients. Clin Infect Dis 2004;39:1848–51
   PubMed Web of Science ®Google Scholar
• Mulligan K, Anastos K, Justman J, et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2005;38:18–22
   PubMed Web of Science ®Google Scholar
• Van L. Estimates of fat-free mass (FFM) by densitometry, dual energy X-ray absorptiometry (DXA), and bioimpedance spectroscopy (BIS) in Caucasian and Chinese-American women. Appl Radiat Isot 1998;49:751–2
   PubMed Web of Science ®Google Scholar
• Kotler DP, Rosenbaum K, Allison DB, et al. Validation of bioimpedance analysis as a measure of change in body cell mass as estimated by whole-body counting of potassium in adults. JPEN J Parenter Enteral Nutr 1999;23:345–9
   PubMed Web of Science ®Google Scholar
• Swanson B, Keithley JK. Bioelectrical impedance analysis (BIA) in HIV infection: principles and clinical applications. J Assoc Nurses AIDS Care 1998;9:49–54
   PubMedGoogle Scholar
• Ockenga J, Manns MP. The impact of body composition analysis in HIV-infected patients: quantifying therapeutic effects. AIDS 1999;13:279–80
   PubMed Web of Science ®Google Scholar
• Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:21–31
   PubMed Web of Science ®Google Scholar
• Capaldini L. Protease inhibitors’ metabolic side effects: cholesterol, triglycerides, blood sugar, and ‘Crix belly’. Interview with Lisa Capaldini M.D. Interview by John S. James. AIDS Treat News 1997;277:1–4
   Google Scholar
• Mooser V, Carr A. Antiretroviral therapy-associated hyperlipid-aemia in HIV disease. Curr Opin Lipidol 2001;12:313–9
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179–93
   Google Scholar
• Heath KV, Hogg RS, Singer J, et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr 2002;30:440–7
   PubMed Web of Science ®Google Scholar
• Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res 2006;4:79–85
   PubMed Web of Science ®Google Scholar
• Kino T, Mirani M, Alesci S, Chrousos GP. AIDS-related lipodystrophy/insulin resistance syndrome. Horm Metab Res 2003;35:129–136
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25–32
   PubMed Web of Science ®Google Scholar
• Mascolini M. On the trail of fugitive fat: the chase turns to NRTIs. J Int Assoc Physicians AIDS Care 1999;5:24–43
   PubMedGoogle Scholar
• Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30(Suppl 2):S135–42
   PubMedGoogle Scholar
• Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231–9
   PubMed Web of Science ®Google Scholar
• Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005;118\(Suppl 2):23S–8
   Google Scholar
• Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093–9
   PubMed Web of Science ®Google Scholar
• Kotler DP, Thea DM, Heo M, et al. Relative influences of sex, race, environment, and HIV infection on body composition in adults. Am J Clin Nutr 1999;69:432–9
   PubMed Web of Science ®Google Scholar
• Jaya G, Lutchman N, Crowther N. Metabolic complications of ART in black South Africans. 14th Conference on Retrovirus’ and Opportunistic Infections, Los Angeles, USA. 25–28 February 2007. [Abstract 796]
   Google Scholar
• Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396–405
   PubMed Web of Science ®Google Scholar
• Maisonneuve C, Igoudjil A, Begriche K, et al. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir Ther 2004;9:801–10
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler S, diRienzo G, et al. and the AIDS Clinical Trials Group 5142 Study Team. Metabolic outcomes of ACTG 5142: a prospective, randomised, phase III trial of NRTI-, PI-, and NNRTI-sparing regimes for initial treatment of HIV-1 infection. 14th Conference on Retrovirus’ and Opportunistic Infections, Los Angeles, USA. 25–28 February 2007. [Abstract 38]
   Google Scholar
• Cameron DW, da Silva B, Arribas J, et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV/3TC. 14th Conference on Retrovirus’ and Opportunistic Infections, Los Angeles, USA. 25–28 February 2007. [Abstract 44]
   Google Scholar
• Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045–52
   PubMed Web of Science ®Google Scholar
• Badiou S, De Boever CM, Dupuy AM, et al. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen. AIDS 2003;17:772–4
   PubMed Web of Science ®Google Scholar
• Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000;2:200–7
   PubMedGoogle Scholar
• Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257–62
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51–57
   PubMed Web of Science ®Google Scholar
• Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks. J Assoc Nurses AIDS Care 2002;13:86–7
   PubMedGoogle Scholar
• Noor MA, Parker RA, O’Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004;18:2137–44
   Google Scholar
• Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18–29
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Alessi MC, Poizot-Martin I, et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992;5:127–31
   PubMedGoogle Scholar
• Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162:433–8
   PubMed Web of Science ®Google Scholar
• Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002;34:55–63
   PubMed Web of Science ®Google Scholar
• Stein JH, Merwood MA, Bellehumeur JB, et al. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler Thromb Vasc Biol 2005;25:399–405
   PubMed Web of Science ®Google Scholar
• Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111–23
   PubMed Web of Science ®Google Scholar
• Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266–73
   PubMed Web of Science ®Google Scholar
• Piketty C, Peytavin G, Trylezinski A, et al. Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz. HIV Med 2002;3:287–9
   PubMedGoogle Scholar
• Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036–46
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130–9
   PubMed Web of Science ®Google Scholar
• Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63–70
   PubMed Web of Science ®Google Scholar
• Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251–4
   Google Scholar
• Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11–18
   PubMed Web of Science ®Google Scholar
• Carpentier A, Patterson BW, Uffelman KD, et al. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005;178:165–72
   PubMed Web of Science ®Google Scholar
• Behrens GM, Meyer-Olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003;17(Suppl 1):S149–54
   PubMed Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003;33: 321–8
   Google Scholar
• Brambilla AM, Novati R, Calori G, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003;17:1993–5
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611–9
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472–7
   PubMed Web of Science ®Google Scholar
• Blazes DL, Decker CF. Symptomatic hyperlactataemia precipitated by the addition of tetracycline to combination antiretroviral therapy. Lancet Infect Dis 2006;6:249–52
   PubMed Web of Science ®Google Scholar
• Gavrila A, Hsu W, Tsiodras S, et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 2005;40:745–9
   PubMed Web of Science ®Google Scholar
• Sheffield CA, Kane MP, Busch RS. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Pharmacotherapy 2007;27: 1449–55
   Google Scholar
• Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 2004;4:763–77
   PubMed Web of Science ®Google Scholar
• Chen D, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002;87: 4845–56
   Google Scholar
• Walker UA, Brinkman K. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction? HIV Med 2001;2:163–5
   PubMedGoogle Scholar
• Fleischman A, Johnsen S, Systrom D, et al. Effects of NRTI, stavudine, on insulin sensitivity and mitochondrial function in muscle of healthy adults. 14th Conference on Retrovirus’ and Opportunistic Infections, Los Angeles, USA. 25–28 February 2007. [Abstract 43]
   Google Scholar
• Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716–23
   Google Scholar
• Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003;42:14711–9
   Google Scholar
• Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417–22
   PubMed Web of Science ®Google Scholar
• Lewis W. Atherosclerosis in AIDS: potential pathogenetic roles of antiretroviral therapy and HIV. J Mol Cell Cardiol 2000;32:2115–29
   PubMed Web of Science ®Google Scholar
• Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735–44
   PubMed Web of Science ®Google Scholar
• Liu Y, Jones M, Hingtgen CM, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 2000;6:1380–7
   PubMed Web of Science ®Google Scholar
• Iurlaro M, Benelli R, Masiello L, et al. Beta Interferon inhibits HIV-1 tat-induced angiogenesis: synergism with 13-cis retinoic acid. Eur J Cancer 1998;34:570–6
   PubMed Web of Science ®Google Scholar
• Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond) 2007;31: 1763–76
   Google Scholar
• Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005;10:207–13
   PubMed Web of Science ®Google Scholar
• Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003;17:1753–62
   PubMed Web of Science ®Google Scholar
• Sutinen J, Kannisto K, Korsheninnikova E, et al. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004;286:E941–9
   PubMedGoogle Scholar
• Lindegaard B, Larsen LF, Hansen AB, et al. Adipose tissue lipin expression levels distinguish HIV patients with and without lipodystrophy. Int J Obes (Lond) 2007;31:449–56
   PubMed Web of Science ®Google Scholar
• Kotler DP, Ionescu G, Johnson JA, et al. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis 2003;37(Suppl 2):S47–51
   PubMedGoogle Scholar
• Martin A, Smith D, Carr A, et al. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study). HIV Clin Trials 2004;5:192–200
   PubMed Web of Science ®Google Scholar
• McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004;38:263–70
   PubMed Web of Science ®Google Scholar
• Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004;18:137–51
   PubMed Web of Science ®Google Scholar
• Aldeen T, Wells C, Hay P, et al. Lipodystrophy associated with nevirapine-containing antiretroviral therapies. AIDS 1999;13:865–7
   PubMed Web of Science ®Google Scholar
• Nolan D. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? Drug Saf 2005;28:1069–74
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005;39:395–400
   PubMed Web of Science ®Google Scholar
• Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33:571–6
   PubMed Web of Science ®Google Scholar
• Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003;18:1039–52
   Google Scholar
• Hanley AJ, Karter AJ, Williams K, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005;112:3713–21
   PubMed Web of Science ®Google Scholar
• Wilson PW, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068–74
   PubMed Web of Science ®Google Scholar
• Sterling JB, Hanke CW. Poly-L-lactic acid as a facial filler. Skin Therapy Lett 2005;10:9–11
   PubMedGoogle Scholar
• Roubenoff R, Schmitz H, Bairos L, et al. Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 2002;34:390–3
   PubMed Web of Science ®Google Scholar
• Visnegarwala F, Grund B, Thomas A, et al. and body composition sub-study investigators of the SMART trial. The effects of intermittent, CD4-guided ART on peripheral limb fat and metabolic parameters: the SMART body composition substudy. 14th Conference on Retrovirus’ and Opportunistic Infections, Los Angeles, USA. 25–28 February 2007. [Abstract 803]
   Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37–49
   Google Scholar
• Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493–505
   PubMed Web of Science ®Google Scholar
• Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805–10
   PubMed Web of Science ®Google Scholar
• Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251–60
   PubMed Web of Science ®Google Scholar
• Sattler F. Body habitus changes related to lipodystrophy. Clin Infect Dis 2003;36:S84–90
   PubMed Web of Science ®Google Scholar
• Hansen BR, Haugaard SB, Iversen J, et al. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis 2004;36:244–53
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195–211
   PubMed Web of Science ®Google Scholar
• Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men – a randomized, placebo-controlled study. AIDS 2006;20:1003–10
   PubMed Web of Science ®Google Scholar
• Badiou S, Merle De BC, Dupuy AM, et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172:273–9
   PubMed Web of Science ®Google Scholar
• Nystrom T, Bratt G, Sjoholm A. Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. J Intern Med 2002;252:570–4
   Google Scholar
• Dube MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006;11:1081–9
   PubMed Web of Science ®Google Scholar
• Samson SL, Pownall HJ, Scott LW, et al. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials 2006;27:518–30
   PubMed Web of Science ®Google Scholar
• Benavides S, Nahata MC. Pharmacologic therapy for HIV-associated lipodystrophy. Ann Pharmacother 2004;38:448–57
   PubMed Web of Science ®Google Scholar
• Walli R, Michl GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000;199:253–62
   PubMedGoogle Scholar
• Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy – a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199–207
   PubMed Web of Science ®Google Scholar
• Prasithsirikul W, Bunnag P. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. J Med Assoc Thai 2004;87:166–72
   PubMedGoogle Scholar
• Viengchareun S, Caron M, Auclair M, Kim MJ, Frachon P, Capeau J, Lombès M, Lombès A. Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther. 2007;12(6):919–29.
   Google Scholar
• Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91:2605–11
   PubMed Web of Science ®Google Scholar
• Mulligan K, Grunfeld C, Hellerstein MK, et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956–62
   PubMed Web of Science ®Google Scholar
• Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099–103
   PubMed Web of Science ®Google Scholar
• D’Amico S, Shi J, Sekhar RV, et al. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 2006;84:204–11
   Google Scholar
• Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002;87:942
   PubMed Web of Science ®Google Scholar
• Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006;7:936–45
   PubMed Web of Science ®Google Scholar
• Falutz J, Allas S, Kotler D, et al. A placebo-controlled, doseranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005;19:1279–87
   PubMed Web of Science ®Google Scholar
• Falutz J, Allas S, Blot K, et al. Effects of TH9507, a growth hormone releasing factor analog, on HIV-associated abdominal fat accumulation: a multicenter, double-blind placebo-controlled trial with 412 randomized patients. 14th Conference on Retrovirus’ and Opportunistic Infections, Los Angeles, USA. 25–28 February 2007. [Abstract 45]
   Google Scholar
• Powderly WG. Current approaches to treatment for HIV-1 infection. J Neurovirol 2000;6(Suppl 1):S8–13
   PubMedGoogle Scholar
• Wong EB, Murdoch D, Wing J, et al. High rates of non-fatal toxicities in a 24-month cohort receiving publicly funded HAART in South Africa. 14th Conference on Retrovirus’ and Opportunistic Infections, Los Angeles, USA. 25–28 February 2007. [Abstract 795]
   Google Scholar
• Rosenkranz SL, Yarasheski KE, Para MF, et al. Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: a pharmacokinetic-pharmacodynamic analysis. Metab Syndr Relat Disord 2007;5:163–73
   PubMedGoogle Scholar
• Janneh O, Hoggard PG, Tjia JF, et al. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther 2003;8:417–26
   PubMed Web of Science ®Google Scholar
• Fontas E, van LF, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056–74
   PubMed Web of Science ®Google Scholar
• Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100:700–5
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169–78
   PubMed Web of Science ®Google Scholar
• Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39:174–80
   PubMed Web of Science ®Google Scholar
• Tashima KT, Bausserman L, Alt EN, et al. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 2003;4:29–36
   PubMed Web of Science ®Google Scholar
• Thomas-Geevarghese A, Raghavan S, Minolfo R, et al. Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Am J Clin Nutr 2005;82:146–54
   Google Scholar
• Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006;8:191–203
   Google Scholar
• Guffanti M, Caumo A, Galli L, et al. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol 2007;156:503–9
   PubMed Web of Science ®Google Scholar
• Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005;18:25–33
   PubMed Web of Science ®Google Scholar